MIRA PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
MIRA$0.62+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $2,832,931 | $4,602,566 |
| Other receivables | - | 11,862 |
| Prepaid expenses | 54,729 | 243,802 |
| Total current assets | 2,887,660 | 4,858,230 |
| Operating lease, right of use assets | - | 5,061 |
| Related party receivable | 35,439 | 69,152 |
| Total assets | $2,923,099 | $4,932,443 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $723,349 | $538,564 |
| Related party accrued interest | - | 14,472 |
| Current portion of operating lease liabilities | - | 5,061 |
| Total current liabilities | 723,349 | 558,097 |
| Total liabilities | 723,349 | 558,097 |
| Stockholders’ Equity | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized and none issued or outstanding. | - | - |
| Common Stock, $0.0001 par value; 100,000,000 shares authorized, 16,560,852 and 14,780,885 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively. | 1,656 | 1,478 |
| Additional paid-in capital | 31,335,815 | 25,657,930 |
| Accumulated deficit | (29,137,721) | (21,285,062) |
| Total stockholders’ equity | 2,199,750 | 4,374,346 |
| Total liabilities and stockholders’ equity | $2,923,099 | $4,932,443 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.